JP2010507578A5 - - Google Patents

Download PDF

Info

Publication number
JP2010507578A5
JP2010507578A5 JP2009533541A JP2009533541A JP2010507578A5 JP 2010507578 A5 JP2010507578 A5 JP 2010507578A5 JP 2009533541 A JP2009533541 A JP 2009533541A JP 2009533541 A JP2009533541 A JP 2009533541A JP 2010507578 A5 JP2010507578 A5 JP 2010507578A5
Authority
JP
Japan
Prior art keywords
cancer
receptor tyrosine
tyrosine kinase
kinase
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009533541A
Other languages
English (en)
Japanese (ja)
Other versions
JP5378222B2 (ja
JP2010507578A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/081841 external-priority patent/WO2008051808A2/en
Publication of JP2010507578A publication Critical patent/JP2010507578A/ja
Publication of JP2010507578A5 publication Critical patent/JP2010507578A5/ja
Application granted granted Critical
Publication of JP5378222B2 publication Critical patent/JP5378222B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009533541A 2006-10-23 2007-10-18 タンパク質キナーゼ調節物質としての二環式トリアゾール Expired - Fee Related JP5378222B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US60/862,552 2006-10-23
US87030906P 2006-12-15 2006-12-15
US60/870,309 2006-12-15
US91376607P 2007-04-24 2007-04-24
US60/913,766 2007-04-24
US95284007P 2007-07-30 2007-07-30
US60/952,840 2007-07-30
PCT/US2007/081841 WO2008051808A2 (en) 2006-10-23 2007-10-18 Bicyclic triazoles as protein kinase modulators

Publications (3)

Publication Number Publication Date
JP2010507578A JP2010507578A (ja) 2010-03-11
JP2010507578A5 true JP2010507578A5 (https=) 2010-12-02
JP5378222B2 JP5378222B2 (ja) 2013-12-25

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533541A Expired - Fee Related JP5378222B2 (ja) 2006-10-23 2007-10-18 タンパク質キナーゼ調節物質としての二環式トリアゾール

Country Status (25)

Country Link
US (1) US8507489B2 (https=)
EP (1) EP2084162B1 (https=)
JP (1) JP5378222B2 (https=)
KR (1) KR20090071612A (https=)
AR (1) AR063520A1 (https=)
AU (1) AU2007309149C1 (https=)
BR (1) BRPI0717320A2 (https=)
CA (1) CA2667428A1 (https=)
CO (1) CO6190620A2 (https=)
CR (1) CR10803A (https=)
DK (1) DK2084162T3 (https=)
EA (1) EA200970403A1 (https=)
ES (1) ES2393130T3 (https=)
IL (1) IL197958A0 (https=)
MA (1) MA30871B1 (https=)
MX (1) MX2009004059A (https=)
NO (1) NO20091618L (https=)
NZ (1) NZ575336A (https=)
PE (1) PE20080893A1 (https=)
PL (1) PL2084162T3 (https=)
PT (1) PT2084162E (https=)
SV (1) SV2009003235A (https=)
TN (1) TN2009000142A1 (https=)
TW (1) TW200835492A (https=)
WO (1) WO2008051808A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2165710A1 (en) * 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ[2,3−b]−ピリジンおよび−ピラジン
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
EP3795573B1 (en) 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1,2,4]三唑并[4,3-b][1,2,4]三嗪类化合物、其制备方法和用途
CN107141309A (zh) 2011-01-11 2017-09-08 桑诺维恩药品公司 杂芳基化合物及其使用方法
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
CN103459396B (zh) * 2011-02-10 2015-08-19 诺瓦提斯公司 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
MX2014011987A (es) 2012-04-03 2014-11-10 Novartis Ag Combinaciones de inhibidores de cinasa de tirosina y su uso.
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术(太仓)有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
WO2014089904A1 (en) 2012-12-10 2014-06-19 Abbvie Inc. Triazinone compounds
WO2014158943A1 (en) * 2013-03-13 2014-10-02 Avon Products, Inc Tyrosinase inhibitors
US9364405B2 (en) 2013-03-13 2016-06-14 Avon Products, Inc. Tyrosinase inhibitors
US20150174034A1 (en) 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
JP6363120B2 (ja) * 2013-03-13 2018-07-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピン化合物の作製方法
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
AU2014262326B2 (en) 2013-05-10 2018-03-22 Jiangsu Hansoh Pharmaceutical Co., Ltd. [1,2,4] triazol [4,3-a] pyridine derivate, preparation method therefor or medical application thereof
WO2017049711A1 (zh) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (ja) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
EP0228061A3 (en) * 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Cephem compounds
JPS62228086A (ja) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd セフエム化合物
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2002083675A2 (en) 2001-04-10 2002-10-24 Merck Sharp & Dohme Limited Inhibitors of akt activity
WO2002083139A1 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
WO2004058769A2 (en) * 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
MX2007001126A (es) * 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
ME01309B (me) 2004-08-26 2013-12-20 Pfizer Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza
WO2006071548A2 (en) 2004-12-27 2006-07-06 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases

Similar Documents

Publication Publication Date Title
JP2010507578A5 (https=)
JP2010507577A5 (https=)
EP1952825A4 (en) NANOMETER-ORIENTED MEDICAMENT FOR THE MAGNETIC THERMOTHERAPY OF MALIGNEN TUMORS
NZ592477A (en) Pyrazolylaminopyridines as inhibitors of fak
IL258880A (en) Diarylhydantoin compounds
AU2009270856A8 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
UA116188C2 (uk) Інгібітори фосфатидилінозит-3-кінази і способи їх застосування
WO2008046085A3 (en) Quinoline derivatives for modulating dna methylation
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
BRPI0814542A2 (pt) Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
WO2007146957A3 (en) Ror1 as a therapeutic target for lung cancer
WO2006037024A3 (en) Salts of decitabine
EP2224919A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND TUMOR-RELATED DISEASES
AP2886A (en) 6.7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
DK1960370T3 (da) Pyridazinonderivater til tumorbehandling
NZ572251A (en) Benzimidazole modulators of vr1
WO2008097466A3 (en) Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors
UA107675C2 (xx) Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом
NZ596861A (en) Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer
WO2009124281A3 (en) Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
WO2009020645A3 (en) Matriptase protein and uses thereof
WO2010034006A3 (en) The putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2.
WO2008116032A8 (en) Compositions and methods for inhibiting tumor cell growth